Search Results
Dec 11, 2025, 06:45 ET Lilly's triple agonist, retatrutide, delivered weight loss of up to an average of 71.2 lbs along with substantial relief from osteoarthritis pain in first successful Phase 3 trial
TRIUMPH-4 clinical trial evaluating the safety and efficacy of the two highest investigational doses of retatrutide, a first-in-class GIP, GLP-1 and glucagon triple hormone receptor agonist, in adults with obesity or overweight and knee osteoarthritis, and without diabetes, as an adjunct
More news about: Eli Lilly and Company
Dec 10, 2025, 22:31 ET Nitinotes anuncia el primer paciente tratado en el ensayo clínico fundamental EASE™
con un solo operador con una técnica de sutura manual ampliamente adoptada. Existe una brecha significativa en el tratamiento entre la terapia con GLP-1, que presenta altas tasas de abandono, y la cirugía bariátrica invasiva. La ESG ofrece una alternativa importante, y la evidencia clínica rigurosa será
More news about: Nitinotes
Dec 10, 2025, 11:15 ET Acosta Group Highlights Four Consumer Predictions for 2026
seek solutions that address health goals such as weight management, digestion, allergen-free, and increased energy levels. Ever-increasing GLP-1 usage is amplifying "precision nutrition" and influencing foodservice and delivery purchases. And the topic of fiber is growing in social media
More news about: Acosta Group
Dec 10, 2025, 09:30 ET Nitinotes Announces First Patient Treated in Pivotal EASE™ Clinical Trial Evaluating the EndoZip™ Automated Suturing System for ESG
compare an automated, single-operator ESG approach to a widely adopted manual suturing technique. There is a significant treatment gap between GLP-1 therapy, which has high dropout rates, and invasive bariatric surgery. ESG offers an important alternative, and rigorously generated clinical evidence
More news about: Nitinotes
Dec 10, 2025, 09:30 ET Nitinotes Announces First Patient Treated in Pivotal EASE™ Clinical Trial Evaluating the EndoZip™ Automated Suturing System for ESG
will compare an automated, single-operator ESG approach to a widely adopted manual suturing technique. There is a significant treatment gap between GLP-1 therapy, which has high dropout rates, and invasive bariatric surgery. ESG offers an important alternative, and rigorously generated clinical evidence
More news about: Nitinotes
Dec 10, 2025, 09:00 ET NEW RESEARCH SHOWS RO HELPS PATIENTS ACHIEVE WEIGHT LOSS AND SAFETY OUTCOMES CONSISTENT WITH CLINICAL TRIALS
nurses. The study is the largest sample of patients with overweight or obesity treated with semaglutide for more than a year via telehealth."As GLP-1s have transformed the obesity treatment landscape, it's become clear that telehealth is a crucial tool to meet the need for large-scale weight management
More news about: Ro
Dec 10, 2025, 08:38 ET New Research from Shed Reveals How Americans Are Really Trying to Lose Weight
research shows that while GLP-1s and high-tech solutions are gaining ground, most Americans still rely on more familiar—but often unsustainable—approaches."Key Findings33% of Americans say friends and family most influenced their interest in GLP-1s—more than fast
More news about: Shed
Dec 10, 2025, 07:00 ET Consumers report feeling lighter, more motivated, mindful, and happier with Montoloeder's Metabolaid® weight-control formulation
supplementation with the polyphenol-rich botanical composition has also been linked to more optimal GLP-1 levels, the gut hormone that has been receiving abundant attention lately. GLP-1 is a natural hormone produced in the body (usually after eating) that helps control blood sugar by
More news about: Monteloeder, S.L.
Dec 10, 2025, 04:15 ET Ascletis Announces China National Medical Products Administration Acceptance of New Drug Application for Denifanstat (ASC40), a First-in-Class FASN Inhibitor for Acne Treatment
once-monthly subcutaneously administered amylin receptor peptide agonist, ASC35, a once-monthly subcutaneously administered GLP-1R/GIPR dual peptide agonist and ASC37, an oral GLP-1R/GIPR/GCGR triple peptide agonist for chronic weight management. Ascletis is listed on the Hong Kong Stock Exchange (1672.HK).For
More news about: Ascletis Pharma Inc.
Dec 09, 2025, 16:00 ET Cirius Therapeutics to Highlight Cardiometabolic Benefits of CIR-0602K at Global Cardiovascular Clinical Trialists (CVCT) Forum 2025
beneficial shifts in adipose tissue phenotype ("bad fat" to "good fat"), both alone and on top of GLP-1 and GLP-1/GIP agonists. In combination with GLP-1/GIP dual agonist tirzepatide, the synergistic transformation of subcutaneous adipose tissue includes dramatic
More news about: Cirius Therapeutics
Dec 09, 2025, 15:30 ET Lilly to build $6 billion facility to manufacture active pharmaceutical ingredients in Alabama
Huntsville site will focus on domestic production of small molecule synthetic and peptide medicines, including Lilly's oral GLP-1, orforglipronCompany plans to create 3,450 manufacturing and construction jobs at Lilly's ninth U.S. manufacturing site
More news about: Eli Lilly and Company
Dec 09, 2025, 15:04 ET Health Systems Embrace New Strategies to Navigate Disruptions
sustain prevention programs. Leaders must plan for the clinical, financial, and operational implications of new therapies like theranostics and GLP-1s, while also protecting vaccine uptake and access for vulnerable populations.Integrate sustainability into core planning. Health systems
More news about: ASHP (American Society of Health-System Pharmacists)
Dec 09, 2025, 09:03 ET CONSUMING TREE NUTS AS SNACKS REDUCES FOOD CRAVINGS AND IMPROVES DIET QUALITY IN MILLENNIALS AT RISK FOR METABOLIC SYNDROME
daily servings of high protein foods.Interestingly, the decreased cravings for sweets were associated with increased GLP-1 blood levels. GLP-1 is a hormone that the body produces to regulate blood glucose and appetite. The tree nuts group reported a significant decrease
More news about: International Tree Nut Council Nutrition Research & Education Foundation
Dec 09, 2025, 08:57 ET OptiMantra-based Online Pharmacies Are Using Alternative Payment Gateways. Here's Why.
management software are turning to alternative payment gateways as they search for stable, reliable credit card processing. Many providers offering GLP-1 weight-loss prescriptions, virtual care, and online therapy services report that account freezes from some mainstream processors have created disruptions
More news about: Organic Payment Gateways
Dec 09, 2025, 06:55 ET Fosun Pharma's Subsidiary Yao Pharma and Pfizer Enter into Exclusive Collaboration and License Agreement
development, use, manufacturing, and commercialization of oral small-molecule glucagon-like peptide-1 receptor (GLP-1R) agonists, including YP05002, and any products containing such oral small molecule GLP-1R agonists as an active ingredient. The license covers all indications for therapeutic, diagnostic, and
More news about: Fosun Pharma
Dec 08, 2025, 12:00 ET Castlight Health Partners With Noom to Expand Access to Personalized Programs for Weight and Chronic Conditions
Castlight's personalized health benefits platform provides seamless access to Noom's health programs including diabetes, GLP-1s and weight support for employers and health plans.SEATTLE and NEW YORK, Dec.
More news about: Castlight Health
Dec 08, 2025, 08:03 ET Grace and Molecule.one to Transform Peptide Building Block Synthesis with AI and Automation
supply chain bottleneck in peptide components—the building blocks essential for manufacturing therapeutics, including the rapidly expanding GLP-1 treatments for weight loss and diabetes. With strong demand for metabolic-disease peptides, the global market is expected to more than double by
More news about: W. R. Grace
Dec 08, 2025, 04:40 ET Ascletis' Oral Small Molecule GLP-1, ASC30, Demonstrated Placebo-Adjusted Weight Loss of 7.7% with Better Gastrointestinal Tolerability in Its 13-Week U.S. Phase II Study in Participants with Obesity or Overweight
1672, "Ascletis") announces today positive topline results in its 13-week Phase II study evaluating ASC30, an oral small molecule GLP-1 receptor (GLP-1R) agonist for the treatment of obesity (NCT07002905)
More news about: Ascletis Pharma Inc.
Dec 08, 2025, 04:40 ET 歌禮口服小分子GLP-1藥物ASC30在肥胖或超重受試者中進行的美國13周II期研究顯示經安慰劑校正後的體重下降高達7.7%，且胃腸道耐受性更佳
View original content:https://www.prnewswire.com/apac/zh/news-releases/glp-1asc3013ii7-7-302635192.htmlSOURCE 歌禮製藥有限公司
More news about: 歌禮製藥有限公司
Dec 06, 2025, 17:25 ET MENU - ORDER AI Announces Global Expansion with New Multilingual Capabilities, Supporting WHO Guidance on Dietary Needs for GLP-1 Users
MENU – ORDER AI, the first real-time GLP-1 dining companion designed to guide users toward High-protein and GLP-1 friendly meal choices, announced that the app now supports a growing international audience with multilingual capabilities.
More news about: MENU - ORDER AI
Dec 06, 2025, 17:15 ET MENU - ORDER AI Announces Global Expansion with New Multilingual Capabilities, Supporting WHO Guidance on Dietary Needs for GLP-1 Users
MENU – ORDER AI, the first real-time GLP-1 dining companion designed to guide users toward High-protein and GLP-1 friendly meal choices, announced that the app now supports a growing international audience with multilingual
More news about: MENU - ORDER AI
Dec 05, 2025, 06:12 ET November in Review: 10 Top Health Press Releases
Vanda Pharmaceuticals Reports Positive Results for Tradipitant in Preventing GLP-1 Induced Nausea and VomitingThis study, which pre-treated patients with either tradipitant or placebo before administering a 1 mg
More news about: PR Newswire
Dec 05, 2025, 06:02 ET 13 Top Press Releases from November
Pharmaceuticals Reports Positive Results for Tradipitant in Preventing GLP-1 Induced Nausea and Vomiting"Tradipitant's effect in reducing nausea and vomiting could significantly improve GLP-1 agonist adherence enabling more people to receive the full therapeutic benefit,"
More news about: PR Newswire
Dec 05, 2025, 01:25 ET 康霈出席第四季法人論壇：揭示CBL-514聯用瘦瘦針最新動物數據 展現四大關鍵優勢、竇根氏症二期成果將獲登國際權威期刊JAAD
更佳的體重維持效果：從根本改善瘦瘦針停藥後復胖之市場痛點GLP-1 類藥物雖能有效降低體重，但僅能「縮小」脂肪細胞體積，並未減少脂肪細胞的「數量」。國外研究指出，即使成功減重，脂肪細胞仍保留「肥胖記憶」，使得減重後的脂肪細胞更容易吸收糖分及脂肪，因脂肪細胞會「記住過去胖的狀態」，進而導致一旦停藥後身體迅速復胖。OI23動物實驗亦觀察到相同現象： GLP-1R停藥三週後，體重回升幅度高達 55.9%。相比之下，CBL-514 與 GLP-1R聯合療法於停藥後僅回升 25.2%，體重維持效果提升 2.2 倍。CBL-514
More news about: 康霈生技
Dec 04, 2025, 16:21 ET FDA Lifts Partial Clinical Hold on Tradipitant for Motion Sickness
clinical development for a variety of indications, including gastroparesis, motion sickness, and the prevention of nausea and vomiting induced by GLP-1 receptor agonists. CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTSVarious statements in this press release, including,
More news about: Vanda Pharmaceuticals Inc.